# A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

> **NCT00428597** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 171 (actual)

## Conditions studied

- Carcinoma, Islet Cell
- Carcinoma, Pancreas

## Interventions

- **DRUG:** sunitinib malate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00428597
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 171 (ACTUAL)
- **Why stopped:** Refer to Detailed Description.
- **Last updated:** 2010-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428597, "A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00428597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*